Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1583–1587. doi: 10.1038/sj.bjc.6690252

Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women

J Romppanen 1, R Keskikuru 2, V Kataja 2, M Eskelinen 3, V-M Kosma 4, K Savolainen 1, M Uusitupa 5, I Mononen 1
PMCID: PMC2362737  PMID: 10188910

Abstract

Using a highly sensitive chemiluminescent enzyme immunoassay, we have evaluated the measurement of serum prostate-specific antigen (PSA) as a potential diagnostic test for differentiation between women with breast cancer and those with benign breast disease. In a controlled study consisting of 284 women with well-documented patient files and matched for age and long-term place of residence, serum samples collected from 90 women with histologically confirmed breast cancer, 94 women with benign breast disease and 100 controls were analysed. Serum total PSA levels in benign breast disease and cancer patients are not statistically different from those of healthy controls. Total PSA levels decrease with age in normal controls and breast cancer patients but not in those with benign breast disease. The total PSA concentration decreases after menopause in healthy women, though not in patients with breast cancer or benign breast disease. Total PSA bore no relation to the histological type or grade of the tumour or the disease stage of the breast cancer patients. In benign breast disease, all mastopathy patients had normal total PSA, whereas elevation of the values was observed in 7% of fibroadenoma patients. Our results show that serum total PSA cannot be used to distinguish between healthy women and/or women with breast cancer or benign breast disease. © 1999 Cancer Research Campaign

Keywords: breast neoplasms, immunoassay, fibroadenoma, mastopathy

Full Text

The Full Text of this article is available as a PDF (89.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borchert G. H., Giai M., Diamandis E. P. Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst. 1997 Apr 16;89(8):587–588. doi: 10.1093/jnci/89.8.587. [DOI] [PubMed] [Google Scholar]
  2. Borchert G. H., Melegos D. N., Tomlinson G., Giai M., Roagna R., Ponzone R., Sgro L., Diamandis E. P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997;76(8):1087–1094. doi: 10.1038/bjc.1997.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Diamandis E. P., Yu H., Melegos D. N. Ultrasensitive prostate-specific antigen assays and their clinical application. Clin Chem. 1996 Jun;42(6 Pt 1):853–857. [PubMed] [Google Scholar]
  4. Diamandis E. P., Yu H., Sutherland D. J. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat. 1994;32(3):301–310. doi: 10.1007/BF00666007. [DOI] [PubMed] [Google Scholar]
  5. Dibbelt L., Vierke G., Wunsche W. Prostate-specific antigen immunoreactivity in women with breast cancer. Clin Chem. 1996 Oct;42(10):1721–1722. [PubMed] [Google Scholar]
  6. Ferguson R. A., Yu H., Kalyvas M., Zammit S., Diamandis E. P. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem. 1996 May;42(5):675–684. [PubMed] [Google Scholar]
  7. Filella X., Molina R., Alcover J., Carretero P., Ballesta A. M. Detection of nonprostatic PSA in serum and nonserum samples from women. Int J Cancer. 1996 Nov 15;68(4):424–427. doi: 10.1002/(SICI)1097-0215(19961115)68:4<424::AID-IJC4>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  8. Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M. A., Diamandis E. P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep;72(3):728–731. doi: 10.1038/bjc.1995.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Howarth D. J., Aronson I. B., Diamandis E. P. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer. 1997;75(11):1646–1651. doi: 10.1038/bjc.1997.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lai L. C., Erbas H., Lennard T. W., Peaston R. T. Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer. 1996 Jun 11;66(6):743–746. doi: 10.1002/(SICI)1097-0215(19960611)66:6<743::AID-IJC6>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  11. Mannello F., Bocchiotti G., Bianchi G., Marcheggiani F., Gazzanelli G. Quantification of prostate-specific antigen immunoreactivity in human breast cyst fluids. Breast Cancer Res Treat. 1996;38(3):247–252. doi: 10.1007/BF01806142. [DOI] [PubMed] [Google Scholar]
  12. Melegos D. N., Diamandis E. P. Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem. 1996 Jun;29(3):193–200. doi: 10.1016/0009-9120(96)00014-e. [DOI] [PubMed] [Google Scholar]
  13. Witherspoon L. R., Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 1997 Apr;157(4):1322–1328. [PubMed] [Google Scholar]
  14. Wu J. T., Zhang P., Astill M. E., Wilson L. W., Lyons B. W., Wu L. L., Stephenson R. PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female serum. J Clin Lab Anal. 1995;9(4):243–251. doi: 10.1002/jcla.1860090406. [DOI] [PubMed] [Google Scholar]
  15. Yu H., Diamandis E. P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C. M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996;40(2):171–178. doi: 10.1007/BF01806212. [DOI] [PubMed] [Google Scholar]
  16. Yu H., Diamandis E. P., Monne M., Croce C. M. Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem. 1995 Mar 24;270(12):6615–6618. doi: 10.1074/jbc.270.12.6615. [DOI] [PubMed] [Google Scholar]
  17. Yu H., Giai M., Diamandis E. P., Katsaros D., Sutherland D. J., Levesque M. A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15;55(10):2104–2110. [PubMed] [Google Scholar]
  18. Yu H., Levesque M. A., Clark G. M., Diamandis E. P. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res. 1998 Jun;4(6):1489–1497. [PubMed] [Google Scholar]
  19. Zarghami N., Grass L., Diamandis E. P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997;75(4):579–588. doi: 10.1038/bjc.1997.101. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES